Results 81 to 90 of about 10,433 (192)

Development, Testing, Parameterisation and Calibration of a Human PBPK Model for the Plasticiser, Di-(2-propylheptyl) Phthalate (DPHP) Using in Silico, in vitro and Human Biomonitoring Data [PDF]

, 2021
Kevin McNally, Craig Sams, Alex Hogg, Annie Lumen, George Loizou   +4 more
openalex   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Use of Physiologically Based Pharmacokinetic (PBPK) Models in Marine Mammal Toxicology [PDF]

, 2012
peer reviewedPhysiologically based pharmacokinetic (PBPK) models are mathematical models that are largely based upon the physiological characteristics of the species and the biochemical properties of the chemical of interest. They quantitatively describe
Blust, Ronny, Covaci, Adrian, Das, Krishna, Weijs, Liesbeth, Yang, Raymond S.H.   +4 more
core  

Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine [PDF]

, 2020
Weize Huang, Lindsay C. Czuba, Nina Isoherranen   +2 more
openalex   +1 more source

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models [PDF]

, 2023
Alexander Denninger, Tim Becker, Ulrich Westedt, Karl Wagner   +3 more
openalex   +1 more source

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach

Frontiers in Pharmacology
IntroductionThe cytochrome P450 enzyme 3A4 (CYP3A4) mediates numerous drug-drug interactions (DDIs) by inducing the metabolism of co-administered drugs, which can result in reduced therapeutic efficacy or increased toxicity.
Cheng-Guang Yang, Tao Chen, Wen-Teng Si, An-Hai Wang, Hong-Can Ren, Li Wang   +5 more
doaj   +1 more source

Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model [PDF]

, 2011
In a study of 133 volunteer subjects, demographic, physiologic and pharmacokinetic data through exposure to 1,3-Butadiene (BD) were collected in order to estimate the percentage of BD concentration metabolized at steady state, and to determine whether
Bois, FY, Mezzetti, M, Ngo, L, Ryan, LM, Smith, TJ   +4 more
core   +3 more sources

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver [PDF]

, 2013
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/109769/1/cptclpt201378 ...
Bai, J P F, Brouwer, K L R, Chu, X, Elsby, R, Fenner, K, Galetin, A, Korzekwa, K, Lai, Y, Matsson, P, Moss, A, Nagar, S, Polli, J W, Rosania, G R, Sugiyama, Y   +13 more
core   +2 more sources